PCOS, Insulin Resistance & GLP-1 for Fertility

🔬

PCOS & GLP-1 Treatment

Understanding how GLP-1 receptor agonists address the metabolic mechanisms underlying polycystic ovary syndrome — and which providers specialize in this approach across the US.

Illustration of PCOS and insulin resistance treatment with GLP-1 medications — GLP-1 medications address insulin resistance — the primary driver of PCOS — leading to restored hormonal balance and improved fertility outcomes.

GLP-1 and PCOS: Why Weight Loss Alone Isn't the Full Story — The Insulin Resistance Mechanism

In women with PCOS, elevated insulin levels directly stimulate the ovaries to produce excess androgens (testosterone), suppress sex hormone-binding globulin (SHBG), and disrupt normal follicle development — creating a cascade of symptoms from irregular periods to hirsutism. GLP-1 medications reduce insulin secretion and improve insulin sensitivity simultaneously, breaking this cycle at the source rather than merely treating downstream symptoms. This is why women on GLP-1 therapy frequently report menstrual cycle normalization within 2–4 months, often before achieving significant weight loss — the insulin-lowering effect alone is therapeutic for PCOS regardless of pounds lost.

Boston IVF / Beth Israel Deaconess

Boston IVF, affiliated with Beth Israel Deaconess Medical Center in Boston, MA, has become a national leader in integrating GLP-1 therapy into PCOS management prior to fertility treatment. Their reproductive endocrinologists routinely prescribe semaglutide or tirzepatide to PCOS patients with BMI over 30 who demonstrate insulin resistance on fasting insulin and HOMA-IR testing. The center offers dedicated PCOS clinics in Boston, Waltham, and Providence, RI, with same-day telemedicine consultations available for patients across New England. Their published outcomes data shows menstrual cycle restoration in 58% of anovulatory PCOS patients within 3 months of GLP-1 initiation.

New England / Academic Center

NYU Langone Fertility Center

NYU Langone Fertility in New York City operates one of the largest PCOS specialty programs in the northeastern US, treating patients from Manhattan, Brooklyn, Queens, Long Island, and New Jersey. Their endocrinology-reproductive medicine co-management model pairs GLP-1 prescriptions (primarily Wegovy and Mounjaro) with cycle monitoring, AMH tracking, and antral follicle counts to document PCOS improvement objectively. NYU's team has been particularly vocal at ASRM (American Society for Reproductive Medicine) conferences about GLP-1's role in restoring natural ovulation, presenting case series of patients who conceived naturally after 6–12 months of GLP-1 therapy. Telehealth follow-up available for established patients in NY and NJ.

New York Metro / Academic Center

UCSF Center for Reproductive Health

The University of California San Francisco's reproductive medicine division in San Francisco, CA, brings a research-driven approach to GLP-1 therapy for PCOS, with ongoing clinical trials examining semaglutide's impact on AMH levels, antral follicle count, and ovarian morphology. UCSF physicians collaborate closely with the UCSF Center for Diabetes and Endocrinology to provide comprehensive metabolic-reproductive co-management. Their PCOS clinic serves patients throughout the Bay Area including Oakland, San Jose, and Marin County. Of note, UCSF researchers have documented normalization of hyperandrogenism (elevated total testosterone, free testosterone, and DHEA-S) in the majority of PCOS patients achieving 10%+ weight loss on GLP-1 therapy.

Bay Area / Research Center

Allara Health & Pollie (Telehealth PCOS Specialists)

Allara Health is a nationwide telehealth platform built specifically for women with PCOS, offering GLP-1 prescriptions alongside nutrition coaching, cycle tracking, and comprehensive metabolic testing. Operating in all 50 states, Allara pairs patients with PCOS-specialized nurse practitioners and physicians who treat insulin resistance as the primary target, prescribing metformin, inositol, and GLP-1 agonists based on individual metabolic profiles. Pollie is a similar PCOS-specific telehealth platform combining dietitian support, health coaching, and physician-supervised GLP-1 therapy for women who prefer a comprehensive virtual PCOS management program. Both platforms integrate with at-home lab testing (fasting insulin, HbA1c, testosterone panel) to monitor treatment progress without in-person visits.

Nationwide Telehealth

Woman consulting with reproductive endocrinologist about PCOS and GLP-1 treatment options

Metformin vs. GLP-1 for PCOS: Choosing the Right Treatment

For decades, metformin was the only insulin-sensitizing medication prescribed for PCOS. GLP-1 receptor agonists have emerged as a superior option for many patients, particularly those with higher BMI, more severe insulin resistance, or intolerance to metformin's gastrointestinal side effects. Key differences include superior weight loss with GLP-1 (15–22% vs. 2–5% with metformin), more dramatic testosterone reduction, and — critically — greater improvement in menstrual regularity. Some reproductive endocrinologists now prescribe both together for synergistic insulin sensitization.

GLP-1 produces 15–22% weight loss vs. 2–5% with metformin alone
Testosterone normalization documented in 60–75% of PCOS patients on GLP-1 at 6 months
Shady Grove Fertility, Northwestern, and Reproductive Medicine Associates all offer GLP-1-PCOS co-management programs

🌱

Fertility Outcomes & Weight Loss on GLP-1

How GLP-1-induced weight loss and insulin sensitization translate into measurable improvements in fertility outcomes — from natural conception to IVF success rates — and what patients need to know about timing and contraception.

Ovulation Restoration & Natural Conception

Many women with PCOS who had not ovulated in years — some since their first period — report spontaneous ovulation within 2–6 months of starting GLP-1 therapy. This restoration occurs through two parallel mechanisms: reduced insulin levels directly lower LH pulse frequency (restoring the LH/FSH ratio critical for follicle selection), and weight loss reduces adipose-derived androgen production. Reproductive endocrinologists at Northwestern Memorial Hospital in Chicago, Mayo Clinic in Rochester MN, and Brigham and Women's Hospital in Boston have all reported natural PCOS pregnancies in patients previously considered candidates for IVF or IUI. Ovulation prediction kits (Clearblue, Mira) are strongly recommended once GLP-1 is initiated, as unexpected ovulation — and conception — is a documented phenomenon.

Natural Fertility Restoration

IUI & IVF Outcomes with Lower BMI

Most major fertility clinics in the US have BMI thresholds for IUI (typically BMI <40) and IVF (often BMI <35–38), with some centers like CCRM Denver and Shady Grove requiring BMI <40 as an absolute cutoff for fresh embryo transfer. GLP-1-induced weight loss is helping thousands of women previously ineligible for fertility treatment cross these thresholds. Published data shows IUI success rates improve approximately 8–12% with each 5-unit BMI reduction, and IVF clinical pregnancy rates increase 12–15% when BMI normalizes from obese to overweight range. Egg quality markers — particularly oocyte maturity rates and fertilization rates — also improve measurably with metabolic normalization.

ART Success Rate Improvement

GLP-1 Discontinuation Timing Before Conception

GLP-1 receptor agonists are classified FDA Category not assigned (insufficient human data) and are considered contraindicated in pregnancy based on animal reproduction studies showing fetal harm. Reproductive endocrinologists at major fertility centers — including RMA of New York, Pacific Fertility Center in San Francisco, and Reproductive Medicine Associates of New Jersey — consistently recommend discontinuing semaglutide 2 months before attempting conception and tirzepatide 1 month before, given the longer half-life of semaglutide (7 days). This allows full clearance before conception. Patients should coordinate GLP-1 discontinuation timing with their reproductive endocrinologist and have active contraception in place during GLP-1 therapy if pregnancy is not currently desired.

Pre-Conception Planning

Contraception Guidance While on GLP-1

A well-documented but underappreciated consequence of GLP-1 therapy in PCOS patients is the unexpected restoration of fertility — women who believed themselves infertile due to chronic anovulation are conceiving unintentionally. ACOG (American College of Obstetricians and Gynecologists) now explicitly advises that women of reproductive age on GLP-1 medications who do not wish to become pregnant should use reliable contraception. Additionally, GLP-1 medications may theoretically reduce absorption of oral contraceptive pills by altering GI transit — some clinicians recommend long-acting reversible contraceptives (IUD, implant) or barrier methods in addition to oral contraceptives during GLP-1 therapy. Coordination between your GLP-1 prescriber and your OB-GYN is strongly recommended.

OB-GYN Coordination

▶ PCOS, Insulin Resistance & GLP-1: What Reproductive Endocrinologists Are Seeing

PCOS & GLP-1 Specialists Nationwide

Major PCOS-GLP-1 programs are available across all US regions: Northeast — Boston IVF (Boston, Waltham, Providence), NYU Langone Fertility (NYC), RMA of New York (Manhattan, NJ), Brigham and Women's PCOS Center (Boston); Mid-Atlantic — Shady Grove Fertility (DC, MD, VA, PA — 30+ locations), Reproductive Medicine Associates of New Jersey; Southeast — Emory Reproductive Center (Atlanta), Baptist Health Fertility (Jacksonville FL), IVF Florida (Margate FL); Midwest — Northwestern Reproductive Medicine (Chicago), Mayo Clinic (Rochester MN), Ohio State Wexner Medical Center (Columbus); Southwest — UT Southwestern Fertility (Dallas), Houston Fertility Institute, Arizona Reproductive Medicine Specialists (Phoenix); West — UCSF (San Francisco), Pacific Fertility Center (SF, LA), CCRM (Los Angeles), Oregon Reproductive Medicine (Portland). Nationwide telehealth PCOS specialists: Allara Health, Pollie, Plume Health, and Alpha Medical serving all 50 states.